Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Traws Pharma secured shareholder approval for Series B and Series C tranches, accessing up to $50 million in financing to support their Phase 2a influenza study.

PUBLIC · TRAWAug 14, 2026•1 day ago

Amount Raised

$50 Million

Round Type

Series B

NewtownBiotechnology

Description

Traws Pharma reported financial results for Q2 2026, highlighting advancements in their clinical programs. The company completed a private placement in April 2026 and is now approved for additional financing contingent on program milestones. They aim to progress their lead product tivoxavir marboxil toward the MHRA resubmission in Q3 2026. The funding will augment their efforts in addressing respiratory viral diseases.

Company Information

Company

Traws Pharma

Location

12 Penns Trail

Newtown, Pennsylvania, United States

About

Traws Pharma’s novel, proprietary, targeted multi-kinase CDK4/6 inhibitor narazaciclib is being evaluated in dose ranging Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole, with the aim to define the recommended phase 2 dose for further development in endometrial cancer. Pre-clinically narazaciclib has shown efficacy in breast cancer cells resistant to palbociclib, assumed due to targeting proteins such as CSF-1 and FGFR implicated in resistance to these agents. Targeting ARK-5 (also known as NUAC 1) suggests additional tumors can be studied when high expression of these proteins are correlated with resistance.

Don't miss Traws Pharma's next move

Get an email the moment Traws Pharma raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Traws Pharma's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.